The DOI matches its Crossref record.
National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network
Abstract
The promise of precision medicine will only be fully realized if the research community can adapt its clinical trials methodology to study molecularly characterized tumors instead of the traditional histologic classification. Such trials will depend on adequate tissue collection, availability of quality controlled, high throughput molecular assays, and the ability to screen large numbers of tumors to find those with the desired molecular alterations. The National Cancer Institute's (NCI) new National Clinical Trials Network (NCTN) is well positioned to conduct such trials. The NCTN has the ability to seamlessly perform ethics review, register patients, manage data, and deliver investigational drugs across its many sites including both in cities and rural communities, academic centers, and private practices. The initial set of trials will focus on different questions: (1) Exceptional Responders Initiative—why do a minority of patients with solid tumors or lymphoma respond very well to some drugs even if the majority do not?; (2) NCI MATCH trial—can molecular markers predict response to targeted therapies in patients with advanced cancer resistant to standard treatment?; (3) ALCHEMIST trial—will targeted epidermal growth factor receptor ( EGFR) and anaplastic lymphoma kinase ( ALK) inhibitors improve survival for adenocarcinoma of the lung in the adjuvant setting?; and (4) Lung Cancer Master Protocol trial for advanced squamous cell lung cancer—is there an advantage to developing drugs for small subsets of molecularly characterized tumors in a single, multiarm trial design? These studies will hopefully spawn a new era of treatment trials that will carefully select the tumors that may respond best to investigational therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
Pharmacogenomics in the clinic
Relling, M. V., & Evans, W. E. (2015) · Nature · doi:10.1038/nature15817 · Cited by 904
The emerging clinical relevance of genomics in cancer medicine
Berger, M. F., & Mardis, E. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0002-6 · Cited by 626
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Amatu, A., Sartore-Bianchi, A., & Siena, S. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000023 · Cited by 601
Metadata
- Authors
- Abrams, J., Conley, B., Mooney, M., Zwiebel, J., Chen, A., Welch, J. J., Takebe, N., Malik, S., McShane, L., Korn, E., Williams, M., Staudt, L., & Doroshow, J.
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2014-05
- Issue
- 34
- Pages
- 71-76
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W2127518316
- Cited by
- 159
- References
- 0
- FWCI
- 23.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network. https://app.cochat.ai/papers/10.14694/edbook_am.2014.34.71
- The paper
- Abrams, J., Conley, B., Mooney, M., Zwiebel, J., Chen, A., Welch, J. J., Takebe, N., Malik, S., McShane, L., Korn, E., Williams, M., Staudt, L., & Doroshow, J. (2014). National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network. American Society of Clinical Oncology Educational Book. https://doi.org/10.14694/edbook_am.2014.34.71
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.